Instil Bio, Inc. noted that ImmuneOnco Biopharmaceuticals announced preliminary safety and efficacy data from the Phase 2 open-label study of IMM2510/AXN-2510 in combination with chemotherapy for front-line advanced non-small cell lung cancer (NSCLC) patients in China. As of July 1, 2025, partial responses were observed in 62% of the 21 efficacy evaluable patients.
Specifically, 80% (8 out of 10) of patients with squamous NSCLC and 46% (5 out of 11) of patients with non-squamous NSCLC demonstrated partial responses. The safety profile of AXN-2510 supported further clinical development, with no dose-limiting toxicities observed in the 33 safety evaluable patients.
There were no treatment-related adverse events leading to dose reduction or death, and only one leading to drug discontinuation. The most common Grade 3+ TRAEs were hematologic, with uncommon clinical sequelae. These preliminary results suggest potential for best-in-class efficacy within the PD-(L)1xVEGF bispecific antibody class.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.